$OMER
OMEROS CORP

2014 Q1 Form 10-K Financial Statement

#000128581914000002 Filed on March 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2012 Q4 2012 Q3
Revenue $100.0K $1.583M $1.417M
YoY Change -90.87% 38.5% 43.57%
Cost Of Revenue $0.00
YoY Change
Gross Profit $100.0K
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $3.770M $3.720M $2.740M
YoY Change -5.51% 77.14% 49.73%
% of Gross Profit 3770.0%
Research & Development $12.02M $9.350M $7.764M
YoY Change 68.61% 5.06% 45.91%
% of Gross Profit 12017.0%
Depreciation & Amortization $80.00K $90.00K $60.00K
YoY Change 14.29% -10.0% -45.45%
% of Gross Profit 80.0%
Operating Expenses $15.78M $9.116M $14.45M
YoY Change 42.01% -17.05% 102.11%
Operating Profit -$15.68M -$7.533M -$13.04M
YoY Change 56.53% -23.5% 111.49%
Interest Expense $672.0K -$360.0K $413.0K
YoY Change 14.48% -32.08% -21.78%
% of Operating Profit
Other Income/Expense, Net -$286.0K $160.0K $159.0K
YoY Change -355.36% -5.88% -7.02%
Pretax Income -$16.64M -$7.730M -$13.28M
YoY Change 58.63% -24.22% 103.99%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$16.64M -$7.734M -$13.28M
YoY Change 58.66% -24.18% 103.87%
Net Earnings / Revenue -16642.0% -488.57% -936.91%
Basic Earnings Per Share
Diluted Earnings Per Share -$538.5K -$298.6K -$514.1K
COMMON SHARES
Basic Shares Outstanding 30.40M shares 25.89M shares 25.86M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2012 Q4 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $52.20M $22.40M $30.60M
YoY Change 292.48% -8.94% -6.99%
Cash & Equivalents $567.0K $1.520M $1.060M
Short-Term Investments $51.60M $20.80M $29.60M
Other Short-Term Assets $143.0K $400.0K $300.0K
YoY Change -71.4% -20.0% 50.0%
Inventory
Prepaid Expenses $1.312M
Receivables $500.0K $1.900M $500.0K
Other Receivables $0.00 $44.00K $0.00
Total Short-Term Assets $54.13M $24.70M $31.44M
YoY Change 242.33% -4.81% -6.99%
LONG-TERM ASSETS
Property, Plant & Equipment $989.0K $1.037M $685.0K
YoY Change -6.52% 40.32% -14.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $267.0K $159.0K $76.00K
YoY Change 86.71% 55.88% -74.67%
Total Long-Term Assets $1.935M $1.875M $1.324M
YoY Change 2.93% 81.33% 10.33%
TOTAL ASSETS
Total Short-Term Assets $54.13M $24.70M $31.44M
Total Long-Term Assets $1.935M $1.875M $1.324M
Total Assets $56.07M $26.58M $32.76M
YoY Change 216.89% -1.51% -6.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.926M $2.632M $2.702M
YoY Change 88.81% 31.47% 68.88%
Accrued Expenses $5.306M $4.757M $6.373M
YoY Change -23.97% -10.92% 145.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $6.400M
YoY Change -100.0% -100.0% 20.75%
Total Short-Term Liabilities $10.23M $8.359M $21.81M
YoY Change -3.33% -55.97% 38.04%
LONG-TERM LIABILITIES
Long-Term Debt $32.21M $20.10M $8.700M
YoY Change 67.77% 48.35% -42.38%
Other Long-Term Liabilities $8.400M $4.600M $3.100M
YoY Change 121.05%
Total Long-Term Liabilities $32.21M $20.10M $11.80M
YoY Change 67.77% 48.35% -21.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.23M $8.359M $21.81M
Total Long-Term Liabilities $32.21M $20.10M $11.80M
Total Liabilities $42.44M $28.46M $33.60M
YoY Change 42.5% -12.52% 8.74%
SHAREHOLDERS EQUITY
Retained Earnings -$271.0M -$214.6M -$206.8M
YoY Change 20.42% 21.83%
Common Stock $339.0K $259.0K $259.0K
YoY Change 30.89% 15.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.212M -$6.531M -$820.0K
YoY Change
Total Liabilities & Shareholders Equity $56.07M $26.58M $32.76M
YoY Change 216.89% -1.51% -6.4%

Cashflow Statement

Concept 2014 Q1 2012 Q4 2012 Q3
OPERATING ACTIVITIES
Net Income -$16.64M -$7.734M -$13.28M
YoY Change 58.66% -24.18% 103.87%
Depreciation, Depletion And Amortization $80.00K $90.00K $60.00K
YoY Change 14.29% -10.0% -45.45%
Cash From Operating Activities -$11.14M -$12.78M -$7.400M
YoY Change 24.21% 73.64% 80.05%
INVESTING ACTIVITIES
Capital Expenditures $6.000K -$400.0K -$90.00K
YoY Change -93.18% 900.0% 800.0%
Acquisitions
YoY Change
Other Investing Activities -$38.91M $8.730M -$29.57M
YoY Change -542.16% 17.97% -722.53%
Cash From Investing Activities -$38.91M $8.330M -$29.66M
YoY Change -546.89% 13.18% -725.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $37.80M $32.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $49.23M 4.910M 30.85M
YoY Change 223686.36% -657.95% 30750.0%
NET CHANGE
Cash From Operating Activities -$11.14M -12.78M -7.400M
Cash From Investing Activities -$38.91M 8.330M -29.66M
Cash From Financing Activities $49.23M 4.910M 30.85M
Net Change In Cash -$817.0K 460.0K -6.210M
YoY Change 241.84% -152.27% -950.68%
FREE CASH FLOW
Cash From Operating Activities -$11.14M -$12.78M -$7.400M
Capital Expenditures $6.000K -$400.0K -$90.00K
Free Cash Flow -$11.15M -$12.38M -$7.310M
YoY Change 23.07% 69.13% 78.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2632000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2329000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4757000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3944000 USD
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
649000 USD
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
575000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2091000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1789000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
235685000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207787000 USD
CY2012 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
511000 USD
CY2013 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
41000 USD
CY2011 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4281000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6252000 USD
CY2011 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1927000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
41000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
511000 USD
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3615583 shares
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7578319 shares
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5878369 shares
CY2013Q4 us-gaap Assets
Assets
16535000 USD
CY2012Q4 us-gaap Assets
Assets
26575000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
14817000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
24700000 USD
CY2013Q4 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
12717000 USD
CY2012Q4 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
20830000 USD
CY2013Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
231000 USD
CY2012Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
231000 USD
CY2011 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
CY2012 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
30000 USD
CY2013 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
CY2012Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
231000 USD
CY2013Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
231000 USD
CY2012Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
99000 USD
CY2013Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
145000 USD
CY2013Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
127000 USD
CY2012Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
98000 USD
CY2013Q4 us-gaap Cash
Cash
1200000 USD
CY2012Q4 us-gaap Cash
Cash
1500000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1520000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1384000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4005000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3278000 USD
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
727000 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-136000 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2485000 USD
CY2013Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
14100000 USD
CY2007Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
12.25
CY2013Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
12.25
CY2007Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
197478 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
197478 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
609016 shares
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7991649 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25897483 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30359508 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25897483 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30359508 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
259000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
304000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38444000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39796000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28546000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
1579000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2183000 USD
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8148000 USD
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
4644000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
970000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2011 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
230000 USD
CY2012 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
0 USD
CY2013 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
0 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
82822000 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
68275000 USD
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
68942000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
59124000 USD
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1866000 USD
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1614000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3775000 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
5707000 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3537000 USD
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.35
CY2011 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.33
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.03
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
2770000 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
68275000 USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
82822000 USD
CY2011 us-gaap Depreciation
Depreciation
435000 USD
CY2012 us-gaap Depreciation
Depreciation
320000 USD
CY2013 us-gaap Depreciation
Depreciation
302000 USD
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
302000 USD
CY2011 us-gaap Depreciation And Amortization
DepreciationAndAmortization
435000 USD
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
320000 USD
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.59
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.39
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.36
CY2011 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.00
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.05
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.00
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
458000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1346000 USD
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
15600000 USD
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M23D
CY2012Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
500000 USD
CY2013Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
615000 USD
CY2011 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2013 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
12500000 USD
CY2012 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10985000 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15819000 USD
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8216000 USD
CY2013Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
308000 USD
CY2012Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
402000 USD
CY2013Q4 us-gaap Incentive From Lessor
IncentiveFromLessor
4500000 USD
CY2012Q1 us-gaap Incentive From Lessor
IncentiveFromLessor
3000000 USD
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
339000 USD
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1169000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2000 USD
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2228000 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-970000 USD
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4718000 USD
CY2012 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
4644000 USD
CY2011 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
0 USD
CY2013 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
3504000 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
438000 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
201000 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-84000 USD
CY2011 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-2254000 USD
CY2013 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1555000 USD
CY2012 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1059000 USD
CY2012Q4 us-gaap Insurance Recoveries
InsuranceRecoveries
3950000 USD
CY2013 us-gaap Interest Expense
InterestExpense
2366000 USD
CY2011 us-gaap Interest Expense
InterestExpense
1884000 USD
CY2012 us-gaap Interest Expense
InterestExpense
1729000 USD
CY2012 us-gaap Interest Paid
InterestPaid
1502000 USD
CY2013 us-gaap Interest Paid
InterestPaid
1709000 USD
CY2011 us-gaap Interest Paid
InterestPaid
1461000 USD
CY2013 us-gaap Investment Income Net
InvestmentIncomeNet
12000 USD
CY2011 us-gaap Investment Income Net
InvestmentIncomeNet
51000 USD
CY2012 us-gaap Investment Income Net
InvestmentIncomeNet
40000 USD
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
71000 USD
CY2012 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
64000 USD
CY2011 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
62000 USD
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2200000 USD
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4300000 USD
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2900000 USD
CY2012Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2012-11-01
CY2013Q4 us-gaap Lease Incentive Receivable Current
LeaseIncentiveReceivableCurrent
0 USD
CY2012Q4 us-gaap Lease Incentive Receivable Current
LeaseIncentiveReceivableCurrent
1488000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26575000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16535000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11873000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8359000 USD
CY2012Q4 us-gaap Litigation Settlement Amount
LitigationSettlementAmount
3950000 USD
CY2013Q4 us-gaap Litigation Settlement Amount
LitigationSettlementAmount
12500000 USD
CY2012Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
3950000 USD
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5600000 USD
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
6116000 USD
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
0 USD
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
5000 USD
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
7295000 USD
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
6683000 USD
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
20103000 USD
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14898000 USD
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
1603000 USD
CY2013Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
1626000 USD
CY2013 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Our most clinically advanced products are derived from our proprietary PharmacoSurgery</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Our PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. Omidria&#8482; (OMS302), our most advanced product, is derived from our PharmacoSurgery platform. In addition to Omidria, we have six other clinical-stage development programs in our pipeline. We also have a deep and diverse pipeline of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor drug targets and the other used to generate antibodies. For each of our products and programs, we have retained all manufacturing, marketing and distribution rights.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Omidria is used for patients undergoing intraocular lens replacement surgery. In July 2013, we submitted a New Drug Application (NDA) to the Federal Drug Administration (FDA) and in September 2013, a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Omidria.</font></div></div>
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21650000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9486000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32973000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16909000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-907000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7909000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34551000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25668000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29695000 USD
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-28546000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-39796000 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-38444000 USD
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-1845000 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-10489000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-13870000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-13276000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-13592000 USD
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-8895000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-8539000 USD
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-7734000 USD
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2011 us-gaap Operating Expenses
OperatingExpenses
31934000 USD
CY2012 us-gaap Operating Expenses
OperatingExpenses
42907000 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
52116000 USD
CY2013Q4 us-gaap Operating Expenses
OperatingExpenses
14071000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
13630000 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
13300000 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
9770000 USD
CY2012Q4 us-gaap Operating Expenses
OperatingExpenses
9116000 USD
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
9568000 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
11115000 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
14453000 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-27410000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-36885000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-50516000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13160000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13434000 USD
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8072000 USD
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-13902000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10020000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13036000 USD
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-7533000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8244000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
61748000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3232000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4253000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4158000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4066000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3976000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
42063000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
2130000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Receivable Current
OperatingLeasesFutureMinimumPaymentsReceivableCurrent
550000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Five Years
OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears
0 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Four Years
OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
480000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Three Years
OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
550000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Two Years
OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
550000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Receivable Thereafter
OperatingLeasesFutureMinimumPaymentsReceivableThereafter
0 USD
CY2013 us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
550000000 USD
CY2011 us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
693000000 USD
CY2012 us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
635000000 USD
CY2012Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
177000000 USD
CY2013Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
205900000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
435000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
495000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
100000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
159000 USD
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
697000 USD
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
574000 USD
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
130000 USD
CY2012Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
44000 USD
CY2013Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
71000 USD
CY2013 us-gaap Paid In Kind Interest
PaidInKindInterest
502000 USD
CY2012 us-gaap Paid In Kind Interest
PaidInKindInterest
354000 USD
CY2011 us-gaap Paid In Kind Interest
PaidInKindInterest
352000 USD
CY2013Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
39000 USD
CY2012Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2200000 USD
CY2012 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
49547000 USD
CY2013 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
47182000 USD
CY2011 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
9000000 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
204000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
642000 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1241000 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
337000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
416000 USD
CY2013 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$959,000</font><font style="font-family:inherit;font-size:10pt;"> was reclassified from current liabilities to non-current liabilities for the year ended December 31, 2012 in the accompanying Consolidated Balance Sheets as we did not have the obligation or intention to pay this rent prior to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. The presentation of the related captions on the cash flow statement for the prior year has also been reclassified to conform to the current period presentation.</font></div></div>
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32306000 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20988000 USD
CY2012Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32300000 USD
CY2013Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16100000 USD
CY2013 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 USD
CY2012 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
6492000 USD
CY2011 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
9942000 USD
CY2011 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
27150000 USD
CY2012 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
49282000 USD
CY2013 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
55295000 USD
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
369000 USD
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
595000 USD
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
662000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3030000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2826000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1037000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
939000 USD
CY2013Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
379000 USD
CY2012Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1934000 USD
CY2013 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2011 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1051000 USD
CY2012 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
6194000 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23718000 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36297000 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31922000 USD
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
679000 USD
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
679000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214577000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-254373000 USD
CY2013 us-gaap Revenues
Revenues
1600000 USD
CY2011 us-gaap Revenues
Revenues
4524000 USD
CY2012 us-gaap Revenues
Revenues
6022000 USD
CY2013Q2 us-gaap Revenues
Revenues
140000 USD
CY2012Q1 us-gaap Revenues
Revenues
1496000 USD
CY2013Q4 us-gaap Revenues
Revenues
169000 USD
CY2012Q2 us-gaap Revenues
Revenues
1526000 USD
CY2012Q3 us-gaap Revenues
Revenues
1417000 USD
CY2012Q4 us-gaap Revenues
Revenues
1583000 USD
CY2013Q3 us-gaap Revenues
Revenues
196000 USD
CY2013Q1 us-gaap Revenues
Revenues
1095000 USD
CY2013Q4 us-gaap Security Deposit
SecurityDeposit
679000 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.57
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
578000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
4281000 USD
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
1927000 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
6252000 USD
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.83
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.88
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.86
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0095
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0166
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0197
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4072707 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2100000 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1100000 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
179259 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.52
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1943301 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.35
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.87
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.31
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
34262000 USD
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5390582 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6969303 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.18
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.38
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
33588000 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6692208 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.27
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.57
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.52
CY2011 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
15000 shares
CY2013 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
40000 shares
CY2012 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
28000 shares
CY2013Q2 us-gaap Share Price
SharePrice
4.14
CY2012Q3 us-gaap Share Price
SharePrice
10.25
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-5554000 USD
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M29D
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
27385000 USD
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M25D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y1M13D
CY2012Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3400000 shares
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3900000 shares
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
185321 shares
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
32306000 USD
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16120000 USD
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
662000 USD
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
369000 USD
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
595000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-18384000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-6531000 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
20470000 USD
CY2013 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
CY2012 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock based compensation expense and accruals for clinical trial and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates. </font></div></div>
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14500000 USD
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9500000 USD
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13600000 USD
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22212351 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28560360 shares
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24155690 shares
CY2013Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
596000 USD
CY2012Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
1842000 USD
CY2013Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
858000 USD
CY2012Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
1447000 USD
CY2013 omer Beginning Year Of Expiry For Net Operating Loss Carryforwards
BeginningYearOfExpiryForNetOperatingLossCarryforwards
2019
CY2012 omer Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
-511000 USD
CY2013 omer Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
-41000 USD
CY2013Q4 omer Classof Warrantor Right Exercise Priceof Warrantsor Rights Weighted Average Price
ClassofWarrantorRightExercisePriceofWarrantsorRightsWeightedAveragePrice
23.85
CY2012Q1 omer Classof Warrantor Right Extension Period
ClassofWarrantorRightExtensionPeriod
P1Y
CY2013Q1 omer Classof Warrantor Right Extension Period
ClassofWarrantorRightExtensionPeriod
P1Y
CY2013Q4 omer Computer Equipment Gross
ComputerEquipmentGross
431000 USD
CY2013Q4 omer Sales Agreement Net Proceeds
SalesAgreementNetProceeds
4900000 USD
CY2013Q4 omer Sales Agreement Numberof Shares Sold During Period
SalesAgreementNumberofSharesSoldDuringPeriod
374000 shares
CY2011 omer Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding
ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding
1689000 USD
CY2012Q4 omer Computer Equipment Gross
ComputerEquipmentGross
394000 USD
CY2012 omer Deferred Rent Reclassification
DeferredRentReclassification
959000 USD
CY2012Q4 omer Deferred Tax Assets Tax Credit Carryforwards Research And Development
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
3800000 USD
CY2013Q4 omer Deferred Tax Assets Tax Credit Carryforwards Research And Development
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
5700000 USD
CY2013Q4 omer Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2013Q4 omer Deferredtaxassetchangeinresearchcreditcarryforwardextensionofcredit
Deferredtaxassetchangeinresearchcreditcarryforwardextensionofcredit
1100000 USD
CY2012Q4 omer Deferredtaxassetchangeinresearchcreditcarryforwardextensionofcredit
Deferredtaxassetchangeinresearchcreditcarryforwardextensionofcredit
1100000 USD
CY2012 omer Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.02
CY2011 omer Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.01
CY2013 omer Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.03
CY2013 omer Ending Year Of Expiry For Net Operating Loss Carryforwards
EndingYearOfExpiryForNetOperatingLossCarryforwards
2033
CY2013 omer Lease Agreement Expense Incurred To Date Reimbursable By Landlord
LeaseAgreementExpenseIncurredToDateReimbursableByLandlord
1400000 USD
CY2012 omer Lease Agreement Expense Incurred To Date Reimbursable By Landlord
LeaseAgreementExpenseIncurredToDateReimbursableByLandlord
602000 USD
CY2013 omer Lease Extension Period
LeaseExtensionPeriod
P5Y
CY2013 omer Lease Term
LeaseTerm
P15Y
CY2013Q4 omer Long Term Debt Maturities Total Principal Payments
LongTermDebtMaturitiesTotalPrincipalPayments
20099000 USD
CY2013Q4 omer Net Operating Leases Future Minimum Payments Due
NetOperatingLeasesFutureMinimumPaymentsDue
59618000 USD
CY2013Q4 omer Net Operating Leases Future Minimum Payments Due Current
NetOperatingLeasesFutureMinimumPaymentsDueCurrent
2682000 USD
CY2013Q4 omer Net Operating Leases Future Minimum Payments Due In Five Years
NetOperatingLeasesFutureMinimumPaymentsDueInFiveYears
4253000 USD
CY2013Q4 omer Net Operating Leases Future Minimum Payments Due In Four Years
NetOperatingLeasesFutureMinimumPaymentsDueInFourYears
3678000 USD
CY2013Q4 omer Net Operating Leases Future Minimum Payments Due In Three Years
NetOperatingLeasesFutureMinimumPaymentsDueInThreeYears
3516000 USD
CY2013Q4 omer Net Operating Leases Future Minimum Payments Due In Two Years
NetOperatingLeasesFutureMinimumPaymentsDueInTwoYears
3426000 USD
CY2013Q4 omer Net Operating Leases Future Minimum Payments Due Thereafter
NetOperatingLeasesFutureMinimumPaymentsDueThereafter
42063000 USD
CY2013 omer Operating Lease Number Of Additional Renewal Option
OperatingLeaseNumberOfAdditionalRenewalOption
2 Leases
CY2012 omer Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding
ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding
60000 USD
CY2013 omer Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding
ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding
0 USD
CY2013Q4 omer Sales Agreement Average Share Price
SalesAgreementAverageSharePrice
13.29
CY2013 omer Sales Agreement Commission Percentage
SalesAgreementCommissionPercentage
0.02
CY2013 omer Sales Agreement Net Proceeds
SalesAgreementNetProceeds
4868000 USD
CY2013 omer Sales Agreement Termination Period
SalesAgreementTerminationPeriod
P10D
CY2013Q4 omer Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber
2896596 shares
CY2013Q1 omer Warrant Expiration Date
WarrantExpirationDate
2014-03-29
CY2013 omer Warrant Expiration Date
WarrantExpirationDate
2014-03-29
CY2013Q4 omer Working Capital
WorkingCapital
2900000 USD
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001285819
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30397366 shares
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013Q2 dei Entity Public Float
EntityPublicFloat
138767404 USD
CY2013 dei Entity Registrant Name
EntityRegistrantName
OMEROS CORP
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Trading Symbol
TradingSymbol
OMER

Files In Submission

Name View Source Status
0001285819-14-000002-index-headers.html Edgar Link pending
0001285819-14-000002-index.html Edgar Link pending
0001285819-14-000002.txt Edgar Link pending
0001285819-14-000002-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
omer-20131231.xml Edgar Link completed
omer-20131231.xsd Edgar Link pending
omer-20131231x10k.htm Edgar Link pending
omer-20131231_cal.xml Edgar Link unprocessable
omer-20131231_def.xml Edgar Link unprocessable
omer-20131231_lab.xml Edgar Link unprocessable
omer-20131231_pre.xml Edgar Link unprocessable
omer-ex1018_thirdamendment.htm Edgar Link pending
omer-ex1020_settlementagre.htm Edgar Link pending
omer-ex1044_eighthamendmen.htm Edgar Link pending
omer-ex121_20131231.htm Edgar Link pending
omer-ex231_consentofindepe.htm Edgar Link pending
omer-ex311_20131231.htm Edgar Link pending
omer-ex312_20131231.htm Edgar Link pending
omer-ex321_20131231.htm Edgar Link pending
omer-ex322_20131231.htm Edgar Link pending
omer-ex991_capitalstockdes.htm Edgar Link pending
picture1300dpi.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending